home All News open_in_new Full Article

BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA

Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with relapsed or refractory mantle cell lymphoma (MCL) BeOne to participate in Project Orbis program, supporting efforts to rapidly advance global access SAN CARLOS, Calif. — BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, […]


today 10 h. ago attach_file Other

attach_file Other
attach_file Economics
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Economics
attach_file Sport
attach_file Society
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Economics
attach_file Events
attach_file Other
attach_file Society


ID: 2531669225
Add Watch Country

arrow_drop_down